Zogenix Inc.’s pure hydrocodone painkiller Zohydro may be abused at a greater rate if approved than combination products on the market, U.S. regulators said.
Food and Drug Administration staff asked outside advisers in a report today to weigh the effectiveness of the extended-release pill against its risk of abuse. The advisers will meet Dec. 7 to decide whether to recommend the medicine’s approval.
